Results 151 to 160 of about 70,554 (222)

Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study. [PDF]

Oncologist
Kotani D, Inoue E, Denda T, Inagaki C, Kashiwada T, Mihara Y, Sugaya A, Suwa Y, Ohta T, Kuramochi H, Oshima K, Yuki S, Shiozawa M, Tsuji A, Muro K, Ichikawa W, Fujii M, Sunakawa Y.   +17 more
europepmc   +1 more source

Clinical outcomes of treatments for patients with refractory metastatic colorectal cancer: a systematic literature review and network meta-analysis. [PDF]

Ther Adv Med Oncol
Taieb J, Yahiaoui S, Choucair E, Yao W, Hauch O, Akers KG, Frederickson AM, Zaanan A.   +7 more
europepmc   +1 more source

IgE to Galactose-α-1,3-Galactose (α-Gal) and Relevance to Ustekinumab First-Dose Infusion Reactions and Allergenicity. [PDF]

JGH Open
Venkat PG, Nehrbas JF, Bortz PS, Platts-Mills TA, Behm BW, Figueroa EJ, Wilson JM.   +6 more
europepmc   +1 more source

Targeting the epidermal growth factor receptor using IgM antibodies: toward next generation cancer immunotherapy. [PDF]

Front Immunol
Somboon K, Bond PJ, Samsudin F.
europepmc   +1 more source

Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study. [PDF]

Cancer Manag Res
Güzel HG, Kıvrak Salim D, Ulukal Karancı E, Acun M, Çatlı MM, Mordağ Çiçek C, Karaman Y, Kaya BE, Terzi A, Köseoğlu Ç, Kahraman EG, Gököz Doğu G, Şahin AB, Karakurt Eryılmaz M, Atağ E, Akay S, Öztürk B.   +16 more
europepmc   +1 more source

Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation. [PDF]

Clin Exp Metastasis
Tirado-Rodríguez G, Ruiz-Montesinos I, Iturrizaga S, García Ruiz de Gordejuela A, Aizpiolea P, Alonso-Alconada D, García-Alonso I, Herrero de la Parte B.   +7 more
europepmc   +1 more source

Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study). [PDF]

Int J Clin Oncol
Suzuki M, Kishino A, Sugasawa M, Fujii T, Nakanome A, Terada T, Hirakawa H, Ueki Y, Matsuo M, Ito R, Hotomi M, Kanno M, Watanabe A, Kitamura Y, Okami K, Endo K, Ono T, Hirano S, Omura G, Omori K, Yamamoto Y, Shimokawa M, Inohara H.   +22 more
europepmc   +1 more source

Targeting cancer expressed EGFR with a humanized monoclonal antibody. [PDF]

Sci Rep
Costa TGF, Sarnovsky R, Zhan J, Maslanka CA, Obiorah I, Xia D, FitzGerald D, Antignani A.   +7 more
europepmc   +1 more source

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. [PDF]

Int J Cancer
Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, Bajor DL, Mukherjee S, Saltzman J, Maguire O, Minderman H, Chatley S, Tarquini ML, Whitworth A, Jurcevic J, Hsiao HH, Knudsen ES, Muhitch JB, Abrams SI, Kalinski P, Segal BH, Bakin A, Yuan G, Wang C, Attwood K, Iyer R, Boland PM.   +24 more
europepmc   +1 more source

Circulating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK-Wip1 Signaling. [PDF]

Drug Des Devel Ther
Zhang J, Zhang M, Wu X, Jing H, Li P, Wang W, Guo X, Zhao Z, Zhu S, Wang Y.   +9 more
europepmc   +1 more source